BYSI catalyst calendar

BeyondSpring Inc.

Upcoming catalysts
2
Cash runway
6 months
Cash & investments
$7M
Phase 3 programs
3

BeyondSpring Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 15, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 15, 2026 est. Next quarterly earnings (projected) Earnings —
June 1, 2029 Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) Trial Milestone Phase 3

Track BYSI alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open BYSI in the tracker

Recent history

DateEventTypePhase
October 6, 2026 8-K filed: Acquisition completed Corporate —
October 2, 2026 8-K filed: Listing / standard notice Corporate —
September 29, 2026 8-K filed: Material agreement, Other event Corporate —
September 18, 2026 8-K filed: Listing / standard notice Corporate —
August 14, 2026 Quarterly results filed (8-K) Earnings —
June 29, 2026 8-K/A filed: Leadership change Corporate —
June 4, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 13, 2026 Quarterly results filed (8-K) Earnings —
March 25, 2026 Quarterly results filed (8-K) Earnings —
December 15, 2025 8-K filed: Other event Filing —
November 21, 2025 8-K filed: Material agreement Corporate —
November 12, 2025 Quarterly results filed (8-K) Earnings —
September 23, 2025 8-K filed: Material agreement, Other event Corporate —
August 13, 2025 Quarterly results filed (8-K) Earnings —
July 3, 2025 8-K filed: Other event Filing —
May 12, 2025 Quarterly results filed (8-K) Earnings —
July 21, 2021 Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC Trial Milestone Phase 3
December 12, 2018 Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 Trial Milestone Phase 3
October 15, 2018 Plinabulin iv Solution in Prevention of TAC Induced Neutropenia Trial Milestone Phase 2
March 20, 2018 Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.